Results 121 to 130 of about 1,470 (198)

Benefit and danger from immunotherapy in myasthenia gravis [PDF]

, 2021
Damato, V.
core   +1 more source

Case report: Efgartigimod combined with intravenous methylprednisolone in a case of co-occurrence of unexplained myasthenia gravis, inflammatory myopathy, and fulminant myocarditis. [PDF]

Front Immunol
Yang H, Pan Z, Yang Y, Wang Y, Cheng B, Qi G.   +5 more
europepmc   +1 more source

A prospective real-world study of efgartigimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. [PDF]

Front Immunol
Nie X, Huang G, Ma Y, Zhu G, Qi W, Zhou H, Wang W, Hao L, Guo X.   +8 more
europepmc   +1 more source

Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod. [PDF]

BMC Neurol
Fu J, Zheng X, Ma X, Qu Q, Cui W, Mao X, Fu W, Lyv H.   +7 more
europepmc   +1 more source

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study. [PDF]

J Neurol
Lin J, Chang T, Xiao L, Hu J, Di L, Yang C, Wu Y, Jiang Y, Zhang J, Bu B, Li Z.   +10 more
europepmc   +1 more source

Treatment of refractory pemphigus vulgaris with efgartigimod

JAAD Case Reports
Matthew Helm, Gracyn Allan, Brigid Deck, Galen Foulke   +3 more
openaire   +3 more sources

Assessing the Value Contribution of Vyvgart^® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis. [PDF]

Adv Ther
Cortés-Vicente E, Guerrero A, Díaz C, Martínez E, Toja-Camba FJ, Abad MR, Serra JM, Trillo JL, Martín Machín C, Gil A.   +9 more
europepmc   +1 more source

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies. [PDF]

Neurotherapeutics
Fuchs L, Vigiser I, Kolb H, Regev K, Drory VE, Dori A, Magalashvili D, Caller T, Kenan G, Mechnik Steen Y, Hellmann M, Wilf-Yarkoni A, Friedman Korn T, Vaknin-Dembinsky A, Bsoul A, Shelly S, Karni A.   +16 more
europepmc   +1 more source

Efgartigimod as an Add-on Therapy for Anti-IgLON5 Disease: A Case Report. [PDF]

Neurol Ther
Wang Z, Huang ZY, Liu L, Zhang YX, Zhang XY.   +4 more
europepmc   +1 more source

Recurrent steroid-intolerant Hashimoto's encephalopathy responsive to single-dose neonatal Fc receptor antagonist: a case report and literature review. [PDF]

BMC Neurol
Wang X, Wang G, Xu J, Bai Y, Yan W, Liu X, Zhang S, Shen R.   +7 more
europepmc   +1 more source